ALPHANCT07935590
Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Participants With OLP: Change From Baseline in Activity Score of the Oral Disease Severity Score (ODSS) at Week 16
Timeframe: Baseline, Week 16
Participants With CLP: Change From Baseline in Modified Lichen Planus Area and Severity Index (LPASI) Score at Week 16
Timeframe: Baseline, Week 16
Participants With LPP: Change From Baseline in Lichen Planopilaris Activity Index (LPPAI) Score at Week 24
Timeframe: Baseline, Week 24
Secondary (24)
Percentage of Participants With Investigator Global Assessment (IGA) Score of 0 or 1 and at Least a 2-point Improvement Over Time
Participants With OLP: Change From Baseline in Activity Score of the ODSS Over Time
Participants With OLP: Change From Baseline in Total ODSS Over Time
Participants With OLP: Change From Baseline in Total Reticulation Erythema and Ulceration (REU) Score Over Time
Participants With OLP: Change From Baseline in Weekly Average of Daily Worst Pain Numeric Rating Scale (NRS) Scores Over Time
Show 19 moreShow less
Participants With OLP: Change From Baseline in Weekly Average of Daily Worst Burning Sensation NRS Scores Over Time
Participants With CLP: Change From Baseline in Modified LPASI Score Over Time
Participants With CLP: Change From Baseline in Weekly Average of Daily Worst Itch NRS Scores Over Time
Participants With LPP: Change From Baseline in LPPAI Score Over Time
Participants With LPP: Change From Baseline in Activity Score Over Time
Participants With LPP: Change From Baseline in Weekly Average of Daily Worst Itch NRS Scores Over Time
Participants With LPP: Change From Baseline in Weekly Average of Daily Worst Pain NRS Scores Over Time
Participants With LPP: Change From Baseline in Weekly Average of Daily Worst Burning Sensation NRS Scores Over Time
Participants With LPP: Change From Baseline in Trichoscopy Parameters: Number of Hairs Over Time
Participants With LPP: Change From Baseline in Trichoscopy Parameters: Hair Diameter Over Time
Participants With LPP: Change From Baseline in Trichoscopy Parameters: Hair Density Over Time
Percentage of Participants in Each Category of Patient Global Impression of Change (PGIC) Over Time
Participants With OLP: Change From Baseline in OLP Symptom Severity Measure (OLPSSM) Total Score Over Time
Participants With OLP: Change From Baseline in Oral Health Impact Profile (OHIP)-14 Total Score Over Time
Participants With CLP and LPP: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score Over Time
Participants With CLP and LPP: Percentage of Participants With 4-point Improvement or Greater From Baseline in DLQI Total Score Over Time
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Peak Concentration of Modzatinib
Trough Concentration of Modzatinib
Arms and interventions
Oral Erosive Lichen Planus (OLP) CohortExperimental
Participants will receive modzatinib or placebo administered orally twice daily (BID) for 16 weeks.
Cutaneous Lichen Planus (CLP) CohortExperimental
Participants will receive modzatinib or placebo administered orally BID for 16 weeks.
Lichen Planopilaris (LPP) CohortExperimental
Participants will receive modzatinib or placebo administered orally BID for 24 weeks.
Drugs: Modzatinib, Placebo
Sites
1 site in 1 country
- Aclaris Clinical SiteSavannah, Georgia, United States